Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
暂无分享,去创建一个
Nandita Mitra | Georgia Chenevix-Trench | Susan L Neuhausen | Fergus Couch | Olufunmilayo I Olopade | Judy E Garber | Fei Wan | Wendy S Rubinstein | F. Couch | O. Olopade | T. Rebbeck | A. Spurdle | W. Rubinstein | G. Chenevix-Trench | R. Greenberg | K. Nathanson | J. Garber | C. Isaacs | S. Neuhausen | N. Tung | P. Ganz | S. Chuai | S. Domchek | C. Singer | S. Narod | H. Lynch | G. Tomlinson | N. Mitra | F. Wan | M. Daly | S. Panossian | J. Weitzel | J. Blum | G. Pfeiler | T. Friebel | Timothy R Rebbeck | Katherine L Nathanson | Christian F Singer | Amanda Spurdle | Susan M Domchek | Mary B Daly | Saarene Panossian | Patricia A Ganz | Jeffrey N Weitzel | Claudine Isaacs | Georg Pfeiler | Nadine Tung | Steven A Narod | Joanne L Blum | Henry T Lynch | Shannon Chuai | Tara M Friebel | Gail E Tomlinson | Roger Greenberg | Saarene Panossian
[1] Bruce A.J. Ponder,et al. Oral Contraceptives and the Risk of Hereditary Ovarian Cancer , 1998 .
[2] D. Januszkiewicz-Lewandowska,et al. I171V germline mutation in the NBS1 gene significantly increases risk of breast cancer , 2008, Breast Cancer Research and Treatment.
[3] R. Scott,et al. The RAD51 135 G>C Polymorphism Modifies Breast Cancer and Ovarian Cancer Risk in Polish BRCA1 Mutation Carriers , 2007, Cancer Epidemiology Biomarkers & Prevention.
[4] S. Eisenberg,et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[5] O. Olopade,et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. , 2006, The Lancet. Oncology.
[6] Paul D P Pharoah,et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. , 2002, Human molecular genetics.
[7] Bo Xu,et al. Convergence of the Fanconi Anemia and Ataxia Telangiectasia Signaling Pathways , 2002, Cell.
[8] F. Couch,et al. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. , 2004, American journal of human genetics.
[9] References , 1971 .
[10] S. Narod. Modifiers of risk of hereditary breast and ovarian cancer , 2002, Nature Reviews Cancer.
[11] Yonghong Xiao,et al. Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.
[12] O. Olopade,et al. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. , 2001, Pharmacogenetics.
[13] R. Shiekhattar,et al. Activation of BRCA1/BRCA2-Associated Helicase BACH1 Is Required for Timely Progression through S Phase , 2007, Molecular and Cellular Biology.
[14] B. Orelli,et al. BRCA2 and homologous recombination , 2001, Breast Cancer Research.
[15] C. Begg. On the use of familial aggregation in population-based case probands for calculating penetrance. , 2002, Journal of the National Cancer Institute.
[16] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[17] J. Chang-Claude,et al. A weighted cohort approach for analysing factors modifying disease risks in carriers of high‐risk susceptibility genes , 2005, Genetic epidemiology.
[18] Chen-Yang Shen,et al. Breast Cancer Risk Is Associated with the Genes Encoding the DNA Double-Strand Break Repair Mre11/Rad50/Nbs1 Complex , 2007, Cancer Epidemiology Biomarkers & Prevention.
[19] S. Elledge,et al. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. , 2000, Genes & development.
[20] N. Pavletich,et al. The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA–ssDNA junction , 2005, Nature.
[21] J. Hopper,et al. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. , 2006, Cancer research.
[22] Maria Chosia,et al. Germline 657del5 mutation in the NBS1 gene in breast cancer patients , 2003, International journal of cancer.
[23] R. Shiekhattar,et al. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. , 2003, Molecular cell.
[24] J. Limon,et al. Germline NBS1 mutations in families with aggregation of Breast and/or ovarian cancer from north-east Poland. , 2007, Anticancer research.
[25] F. Couch,et al. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. , 2007, American journal of human genetics.
[26] Ashok R Venkitaraman,et al. Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.
[27] Susan L Neuhausen,et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.
[28] A. Kluska,et al. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland , 2006, International journal of cancer.
[29] M. Stratton,et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus , 1996, Nature Genetics.
[30] R. Scully,et al. Molecular Functions of BRCA1 in the DNA Damage Response , 2004, Cancer biology & therapy.
[31] A. Whittemore,et al. Breast and Ovarian Cancer in Relatives of Cancer Patients, with and without BRCA Mutations , 2006, Cancer Epidemiology Biomarkers & Prevention.
[32] C. Mathew,et al. Interaction of FANCD2 and NBS1 in the DNA damage response , 2002, Nature Cell Biology.
[33] S. West,et al. Distinct functions of BRCA1 and BRCA2 in double-strand break repair , 2001, Breast Cancer Research.
[34] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.
[35] John L Hopper,et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource , 2006, Breast Cancer Research.
[36] R. Greenberg. Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network , 2008, Chromosoma.
[37] L. Excoffier,et al. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. , 1995, Molecular biology and evolution.
[38] P. Devilee,et al. NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia , 2005, International journal of cancer.
[39] T. Dörk,et al. NBS1 variant I171V and breast cancer risk , 2008, Breast Cancer Research and Treatment.
[40] R. Eeles,et al. A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers , 2004, British Journal of Cancer.
[41] R. Greenberg,et al. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. , 2006, Genes & development.
[42] N. Schork,et al. Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease. , 2001, Genome research.
[43] B. Modan,et al. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[44] Chronic Disease Division. Cancer facts and figures , 2010 .